[Archived Hypothesis]

Target: %s Composite Score: 0.300 Price: $0.30 Citation Quality: Pending Status: archived

☰ Compare ⚛ Collideinteract with this hypothesis

⚠ Missing Evidence⚠ No Target Gene⚠ Thin Description⚠ Low Validation Senate Quality Gates →

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.300

Top 91% of 1512 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

F Mech. Plausibility 15% 0.00 Top 50%

F Evidence Strength 15% 0.00 Top 50%

F Novelty 12% 0.00 Top 50%

F Feasibility 12% 0.00 Top 50%

F Impact 12% 0.00 Top 50%

F Druggability 10% 0.00 Top 50%

F Safety Profile 8% 0.00 Top 50%

F Competition 6% 0.00 Top 50%

F Data Availability 5% 0.00 Top 50%

F Reproducibility 5% 0.00 Top 50%

Evidence

5 supporting | 0 opposing

Citation quality: 0%

Debates

1 session A

Avg quality: 0.81

From Analysis:

Legacy Pre-Pipeline Hypothesis Import

Hypotheses created before the analysis pipeline was established (pre-2026-04-01)

→ View full analysis & debate transcript

Description

No description available

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

5 citations 0 with PMID Validation: 0% 5 supporting / 0 opposing

✓ For (5)

No supporting evidence

No opposing evidence

(0) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 5CLIN 0GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
34125170	Supporting	MECH	-	-	-	-	-	-
35345957	Supporting	MECH	-	-	-	-	-	-
34554191	Supporting	MECH	-	-	-	-	-	-
29134275	Supporting	MECH	-	-	-	-	-	-
37736290	Supporting	MECH	-	-	-	-	-	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

34125170

35345957

34554191

29134275

37736290

✗ Opposing Evidence 0

No evidence recorded

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-26 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Legacy Pre-Pipeline Hypotheses: Neurodegeneration

Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease

Mechanism: Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a "prion-like" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.

Target: RAB27A (exosome biogenesis), GBA (lysosomal function), LRRK2 G2019S (enhances exosome release)

Supporting Evidence:

Braak et al. (2003) Neurobiology of

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Legacy Pre-Pipeline Hypotheses

General Methodological Concerns (Cross-Cutting Issues)

Before evaluating individual hypotheses, several systemic weaknesses affect the entire corpus:

1. Animal Model Validity Crisis
All seven hypotheses rely heavily on transgenic mouse models (5xFAD, MPTP, α-syn transgenic mice) with well-documented limitations:

Mouse neuroimmune systems differ substantially from humans
Accelerated pathology timelines may not reflect human disease etiology
Many therapeutic candidates successful in rodents have failed in human trials (anti-

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Comprehensive Feasibility Assessment: Legacy Neurodegeneration Hypotheses

Preamble

This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidence strength, translational readiness, and development feasibility are rated on consistent scales to enable cross-hypothesis comparison. Where the Skeptic's revised confidence scores diverge from my independent assessment, I note the discrepancy and rationale.

Evaluation Framework

| Domain | Assessment Criteria |
|--------|---------------------|
| Druggability | Target tractability, ch

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

High

1.2544

Events (7d)

⚡ Price Movement Log Recent 9 events

	Event	Price	Change	Source	Time
💬	Debate Round	$0.066	▼ 65.9%	market_dynamics	2026-04-14 06:26
💬	Debate Round	$0.194	▲ 1835.0%	market_dynamics	2026-04-14 03:10
📄	New Evidence	$0.010	▼ 95.1%	market_dynamics	2026-04-14 03:09
📊	Score Update	$0.202	▲ 60.5%	market_dynamics	2026-04-14 01:39
📄	New Evidence	$0.126	▲ 69.6%	market_dynamics	2026-04-13 23:49
📊	Score Update	$0.074	▼ 61.6%	market_dynamics	2026-04-13 23:47
📄	New Evidence	$0.194	▼ 26.0%	market_dynamics	2026-04-13 22:10
💬	Debate Round	$0.262	▲ 237.5%	market_dynamics	2026-04-13 21:55
📊	Score Update	$0.077		market_dynamics	2026-04-13 21:18

Clinical Trials (0) Relevance: 15%

No clinical trials data available

📚 Cited Papers (0)

No linked papers yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score

1.00

93.6th percentile (760 hypotheses)

Tokens Used

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

1.00 tokens

Lower is better (baseline: 2000)

Cost per Citation

1.00 tokens

Lower is better (baseline: 1000)

Cost per Score Point

5.00 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.100

10% weight of efficiency score

Adjusted Composite

0.400

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

No related hypotheses found

Estimated Development

Estimated Cost

$2M

Timeline

2.0 years

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

Source Analysis

Legacy Pre-Pipeline Hypothesis Import

neurodegeneration | 2025-12-31 | archived

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alz

Score: 0.82 · TREM2

Complement C1q-Mediated Synaptic Pruning Drives Early Cognitive Declin

Score: 0.77 · C1Q

C9orf72 Hexanucleotide Repeat Dipeptide Repeat Proteins Inhibit Nucleo

Score: 0.74 · NUP98

c-Abl Tyrosine Kinase Activation Drives α-Synuclein Phosphorylation an

Score: 0.60 · ABL1

Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkins

Score: 0.59 · RAB27A

→ View all analysis hypotheses

[Archived Hypothesis]

Description

Dimension Scores

✓ Supporting Evidence 5

✗ Opposing Evidence 0

Legacy Pre-Pipeline Hypotheses: Neurodegeneration

Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease

Critical Evaluation of Legacy Pre-Pipeline Hypotheses

General Methodological Concerns (Cross-Cutting Issues)

Comprehensive Feasibility Assessment: Legacy Neurodegeneration Hypotheses

Preamble

Evaluation Framework

Price History

Clinical Trials (0) Relevance: 15%

📚 Cited Papers (0)

📙 Related Wiki Pages (0)

📓 Linked Notebooks (0)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (5)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions

Knowledge Subgraph (0 edges)

Source Analysis

Legacy Pre-Pipeline Hypothesis Import

Community Feedback

Same Analysis (5)